Placebo + Psilocybin for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 1 Nov 2017: Trial started, NCT03341689
  2. 14 Nov 2017: Trial registered, NCT03341689
  3. 6 Jan 2020: Trial registered, NCT04218539
  4. 10 Aug 2021: Trial started, NCT04218539

The trials

NCT03341689: Psilocybin for the Treatment of Migraine Headache

State
Completed
Phase
Phase 1
People
14 taking part
Started
1 Nov 2017
Primary completion
30 Apr 2021
Arms
Placebo/Low Dose Psilocybin, Placebo/High Dose Psilocybin, Low Dose Psilocybin/Placebo, High Dose Psilocybin/Placebo
Results
None posted
  1. 1 Nov 2017: Trial started
  2. 14 Nov 2017: Trial registered
  3. 31 Oct 2021: Trial completed

NCT04218539: Repeat Dosing of Psilocybin in Migraine Headache

State
Completed
Phase
Phase 1
People
18 taking part
Started
10 Aug 2021
Primary completion
5 Nov 2023
Arms
Placebo/Psilocybin, Psilocybin/Placebo
Results
None posted
  1. 6 Jan 2020: Trial registered
  2. 10 Aug 2021: Trial started
  3. 5 Nov 2023: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.